2Schweitzer S O. Pharmaceutical economics and policy [M ]. New York: Oxford University Press, 1997.
3Ess S M, Schneeweiss S, Szucs T D.European healthcare policies for controlling drug expenditure[J]. Pharmacoeconomics, 2003, 21 (2) : 89-103.
4Meng Q Y, Cheng G, Silver L, et al. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals[J]. Health Policy & Planning, 2005, 20 (3): 185-196.
5Soumerai S B, McLaughlin T J, Ross-Degnan., et ol. Effects of a limit on medicaid drug-reimbursement benefits on the use of psychotroic agents and acute mental health services by patients with schizophrenia [J ]. N Eng J Med, 1994, 331(10) : 650-655.
6Towse A. The efficient use of pgarmaceuticals: does Europe have any lessons for a medicare drug benefit? [J]. Health Affairs, 2003, 22 (3) : 42-46.
7Steinke D T, MacDonald T M, Davey P G. The doctor-patient relationship and prescribing patterns: a view from primarv care [J]. Pharmacoeconomics, 1999, 16(6): 599-603.
8Schweitzer S O, Schweitzer M E, Sourty-LeGuellec M-J. Is there a US drug lag? The timing of pharmaceutical approvals in the G-7 countries and Switzerland [J]. Medical Care Research and Review, 1996, 53(2): 162-178.
9Lichtenberg F.Pharmaceutical Innovation, Mortality Reduction, and Economic Growth[R]. New York: National Bureau for Economic Research, 1998.
10Allen,F.,Faulhaber,G.Signaling by underpricing in the IPO market.Journal of Financial Economics,1989,23:303-324.
